Objective: One of the multiple health benefits of soy protein or its isoflavones may be their purported favorable effect on body composition. We examined the effect of isoflavones extracted from soy protein on overall and regional body composition, taking into account appetitive hormones as potential mediators, as well as the direct effect on appetitive hormones.
S oybeans are promoted as a healthy food with multiple health benefits. One purported benefit is that soy protein or its isoflavones may favorably affect body composition. Animal studies have shown that hamsters, 1 ovariectomized rats, 2 mice, 3 and monkeys 4 fed a diet containing individual isoflavones (genistein, daidzein, or glycitein) or isoflavonerich soy protein had less body fat compared with control animals. To date, a few small-scale human studies have examined the association between isoflavone intake and body composition. Perimenopausal women who consumed isoflavone-rich (80 mg/d) soy protein for 6 months had slightly but significantly lower thigh fat mass and greater hip lean mass compared with women who consumed either isoflavone-poor soy protein or whey protein (control) powder. 5 Obese sarcopenic postmenopausal women (n = 18) who consumed isoflavone supplements (70 mg/d) for 6 months experienced a significant increase in appendicular leg fat-free mass and muscle mass index (appendicular fat-free mass/height 2 ) compared with a placebo group (n = 6). 6 Nine postmenopausal women who consumed a soy protein shake with 160 mg isoflavones for 3 months showed smaller increases in total and subcutaneous abdominal fat compared with an isocaloric casein control group (n = 6), although visceral fat, total body fat, or lean mass did not differ between groups. 7 In a randomized controlled trial, 100 mg/d of isoflavones (supplement form) administered to postmenopausal Japanese women for 24 weeks resulted in a significant reduction in total body fat and prevented an increase in body mass index (BMI) compared with the control group. 8 Although the results of human studies vary, in part due to differences in methodology, the above studies suggest some association between isoflavone intake and body composition. Thus, a well-designed, long-term prospective clinical trial should help clarify whether soy isoflavones indeed exert a physiologically important effect on body composition, particularly central adiposity, in humans. Isoflavones may affect body composition directly, for example, via an estrogen receptorY mediated mechanism 9 by altering the metabolic activity of adipocytes 3 or indirectly by mediating the action of insulin, leptin, ghrelin, and adiponectin, hormones thought to be involved in the regulation of body composition.
This randomized, placebo-controlled, multicenter clinical trial examined the effects of two doses (80 or 120 mg) of soy isoflavones taken for 12 months on overall (whole-body fat mass and whole-body lean mass) and regional (androidal fat mass and androidal-to-gynoidal fat mass ratio) body composition in healthy postmenopausal women. This study also determined the response to soy isoflavone tablets on these outcomes of interest, but taking into account potential mediators of body composition (insulin, leptin, ghrelin, and adiponectin) and confounding factors (age or time since last menstrual period [TLMP], aspartate aminotransferase [AST], physical activity, and dietary intake of energy, protein, and fat). We also assessed the effect of isoflavone tablets on circulating concentrations of insulin, leptin, ghrelin, and adiponectin.
METHODS

Overall study design
This project was ancillary to the Soy Isoflavones for Reducing Bone Loss (SIRBL) study, a randomized, double-blind, placebo-controlled multicenter (Iowa State University [ISU] and University of California at Davis [UCD]) clinical trial. The parent study examined the effect of two doses (80 vs 120 mg/d) of soy proteinYderived isoflavones for 36 months on bone loss in healthy postmenopausal women (age, 45 to 65 y) who were at risk for osteoporosis. This ancillary project focused on the effect of soy isoflavone tablets for 12 months on overall body composition and central adiposity and whether appetitive hormones mediated this anticipated effect. The respective institutional review boards at ISU (ID 02-199) and at UCD (ID 200210884-2) approved our study protocol, consent form, and subject-related materials. Approvals for the dual-energy x-ray absorptiometry (DXA) procedures were obtained from each institution's institutional review board and the State Department of Public Health in Iowa and California. We explained the details of the study verbally and in writing to each participant before she signed an informed consent form.
Participant recruitment, screening, and eligibility
Women were recruited (2003) (2004) (2005) throughout the state of Iowa and in the Sacramento and Bay Area regions in California primarily through direct mailing lists, stories in local newspapers, and local/regional radio advertisements. Responders (N = 5,255) were initially screened via telephone to identify healthy women (nonosteoporotic, without diseases or conditions, not taking hormones or medications, nonsmokers) 65 years or younger who had experienced natural menopause (within 9 mo to 10 y), were not experiencing excessive vasomotor symptoms, were nonsmokers, and had a BMI ranging from 18.5 through 29.9 kg/m 2 . The parent SIRBL project established the inclusion/exclusion criteria. We excluded vegetarians and high alcohol consumers (more than seven servings per week), as well as those who were diagnosed with chronic disease, had a first-degree relative with breast cancer, or chronically used medication (current: cholesterol lowering and/or antihypertensive; past 12 mo: oral hormones/estrogen or selective estrogen receptor modulators; past 6 mo: estrogen/ progestogen creams or calcitonin; ever: bisphosphonates; past 3 mo: antibiotics).
Women who met the initial screening criteria (n = 677) were invited to the clinic for further eligibility screening, including bone mineral density (BMD) assessment using DXA. The SIRBL project focused on disease prevention rather than treatment; thus, we excluded women with BMD lumbar spine and/or proximal femur T-scores that were low (91.5 SD below young adult mean) or high (91.0 SD above mean) or with evidence of previous or existing spinal fractures. Once a woman qualified based on BMD, blood was drawn for a chemistry profile. We excluded women with evidence of diabetes mellitus (fasted glucose Q6.93 mmol/L [126 mg/dL]); abnormal renal, liver (increased enzymes), and/or thyroid function; or increased lipid levels (low-density lipoprotein cholesterol 94.10 mmol/L [160 mg/dL] or triacylglycerol 92.25 mmol/L [200 mg/dL]). Based on our entry criteria, 255 women were randomized to treatment in the parent trial. We excluded 13 women from UCD from this analysis because they did not meet the entry criteria (11 had thickened endometrium, 1 had breast cancer, and 1 could not provide a baseline blood sample). We excluded an additional 13 women who did not have body composition data at either 6 or 12 months because they dropped out of the study, resulting in a sample size of 229 eligible women ( Fig. 1 ). For this ancillary project, we had 79 women in the placebo group, 78 women in the 80 mg/d group, and 72 women in the 120 mg/d group.
Randomization to treatment and tablet formulation
To meet the objectives of the parent project, participants at each location (ISU and UCD) were stratified according to initial proximal femur BMD (high, medium, or low) based on National Health and Nutrition Examination Survey III database population values: (1) high: greater than the mean (zero) but equal to or less than +1.0 SD above the mean; (2) medium: equal to or less than the mean but greater than j0.75 SD below the mean; or (3) low: less than Y0.75 SD through Y1.5 SD below the mean. Once participants met inclusion criteria, they were randomly assigned to one of three treatment groups within each BMD strata at each location: (1) placebo control, (2) 80 mg isoflavones, or (3) 120 mg isoflavones. Placebo material, devoid of isoflavones, consisted of maltodextrin (90%) and caramel color (10%), mixed and spray dried to produce a brown powder, which mimicked the isoflavone extract. Active tablets contained the same excipients as those of the placebo tablets. All treatment tablets (identical in appearance) contained the same amount of sorbitol, magnesium stearate, and dicalcium phosphate. The ratio of genistein to daidzein to glycitein (aglycone form) in these tablets was 1.3:1:0.3, similar to what is found in soybeans. An independent researcher (Patricia Murphy) at ISU confirmed that the actual versus formulated isoflavone doses (mean T SD) were similar to those tested by The Archer Daniels Midland Company (Decatur, IL): control = 0 versus 0.3 T 0.4 mg; 80 mg = 89.5 T 5.0 versus 84.3 T 4.5 mg; and 120 mg = 124.0 T 7.7 versus 122.5 T 3.4 mg, respectively. Participants in each group were instructed to take three compressed tablets per day. Bottles did not indicate treatment assignment to preserve the double-blind nature of the study.
Data collected
We used data that were collected at baseline and at 6 and 12 months for these analyses. The primary outcomes of interest included whole-body lean and fat mass, regional (specifically central) fat mass, and fasting concentrations of insulin, leptin, ghrelin, and adiponectin. We obtained anthropometric measurements using trained anthropometrists according to standard protocols. Standing height was taken twice (average value recorded) with a wall-mounted stadiometer (model S100; Ayrton Corp., Prior Lake, MN), and weight was measured using an ABCO Health-o-Meter scale (Bridgeview, IL). Women changed into hospital scrubs or shorts and a T-shirt and removed their shoes, belts, watches, and jewelry for the duration of anthropometric and body composition assessment.
Body composition measurements were obtained by certified DXA operators using matching DXA instruments (Delphi W; Hologic Inc., Waltham, MA) at each site, which were calibrated daily. Cross-training of the operators ensured standardized data collection. To further ensure quality control, one operator assessed overall composition from the whole-body DXA scans from both sites. Regional adiposity FIG. 1. Participant screening and enrollment flowchart. We excluded 13 women from UCD in this analysis because they did not meet entry criteria and were deemed protocol violators (11 due to a thickened endometrium, 1 with breast cancer, and 1 without a baseline blood sample). In addition, 13 women (11 at UCD and 2 at ISU) had missing body composition data at the 6-and/or 12-month time points because they were lost to follow-up and were thus excluded from the analysis. Three women discontinued treatment but completed the trial; their data were included in the analysis. TVU, transvaginal ultrasound; LTFU, lost to follow-up; BMD, bone mineral density; AE, adverse event; UCD, University of California at Davis; ISU, Iowa State University.
analysis was performed by one analyzer (L.R.) who sectioned each whole-body DXA scan into waist, hip, and thigh regions based on bone landmarks 10 using special software (Discovery Version 12.3:7). The waist region included the first lumbar through the fourth lumbar vertebrae. The hip region began below the fourth lumbar vertebrae and extended to the tip of the greater trochanter of the femur. We calculated androidal fat mass for each participant: waist + hip mass. The thigh region extended superiorly from the greater trochanter to the approximate midpoint between the edge of the thigh region and lateral condyle of the femur. The lateral edge of each region was extended horizontally to encompass all tissue. This DXA analysis provided an estimate of the fat and lean mass within each of these three regions. We calculated the androidal-to-gynoidal fat mass ratio for each participant: waist + hip fat mass/thigh fat mass.
Phlebotomists collected fasted (9 h) blood samples between 7:00 and 8:00 AM. We centrifuged blood samples for 15 minutes (4-C) at 1,000 Â g to separate serum (allowed to clot for 30 min before centrifugation) and plasma from whole blood and stored them in aliquots at j80-C until analyses. Certified clinical laboratories (LabCorp, Kansas City, KS, at ISU; and UCD Medical Center, Sacramento, CA, at UCD) analyzed our blood samples for general health markers, including a complete blood count with differential, chemistry panel, and thyroid screen. We determined plasma (heparinized) adiponectin, serum leptin, serum insulin, and plasma (EDTA treated) total ghrelin concentrations in duplicate with radioimmunoassay kits (Linco Research, St. Charles, MO) using a Cobra II series auto-gamma counting system (Packard Instrument Company, Meriden, CT). The ISU site performed these hormone analyses using manufacturer-provided quality controls and in-house quality control sera/plasma to calculate interassay coefficients of variation (CVs); we used duplicate samples to calculate intra-assay CVs. The intra-assay and interassay CVs, respectively, for adiponectin, leptin, insulin, and ghrelin were 1.5% and 1.7%, 2.4% and 2.7%, 2.6% and 4.0%, and 3.4% and 3.1%. Based on the chemistry profiles of participants at each time point, we included one liver enzyme (AST) that was available for all participants in the regression analyses. Serum AST activity is widely used as reliable surrogate marker of fatty liver. 11 We included this liver enzyme because of the relationship between nonalcoholic fatty liver disease and central adiposity, both of which are related to an unfavorable cardiometabolic profile. 12 During the enrollment phase, trained interviewers administered two questionnaires to participants: a nutrition history 13 and a health and medical history adapted with modifications. 13 We asked participants to cease taking herbal therapies and/or dietary supplements before baseline testing. We assessed dietary intake at each time point using a semiquantitative food frequency questionnaire from Block Dietary Data Systems (Berkeley, CA). Selected outcomes from the questionnaires that could potentially influence body composition were included in the statistical analyses as covariates. We assessed physical activity at each time point using the Paffenbarger physical activity recall 14 to obtain activity information from the previous time period, including walking, climbing stairs, and engaging in sports and recreational activity. To aid participants in recalling activities, we provided a list of common recreational and daily (ie, cleaning, gardening, yard work, and farm work) activities categorized by intensity (e5.0, 5.1-6.9, or Q7.0 metabolic equivalents). Each reported recreational or work-related activity was summed using metabolic equivalents of 4 (light), 6 (medium), or 8 (heavy), providing an estimate of weekly energy expenditure.
Statistical analyses
We performed statistical analyses using SAS (version 9.1; SAS Institute, Cary, NC) and considered results statistically significant (two sided) at P e 0.05. Our analyses included women with complete data at 6 and 12 months beyond the initial baseline value, regardless of treatment compliance (n = 229). We report the descriptive statistics for 229 women using mean T SD for most variables because they were normally distributed. We used median values and range for ghrelin because its data distribution was skewed. We conducted repeated-measures analysis of variance using the PROC MIXED procedure in SAS to examine the effects of treatment over time for each body composition outcome (whole-body lean mass, whole-body fat mass, androidal fat mass, and androidal-to-gynoidal fat mass ratio). To account for the variation in different observations of body composition outcomes among women, the response vector for each woman included baseline measurements to examine changes from baseline. We used restricted maximum likelihood estimation to obtain estimates of variances and correlations between repeated measures (default in SAS for PROC MIXED). For all models but one (whole-body fat mass), the most appropriate covariance model for the dependence structure in the repeated measurements was an unstructured (unrestricted) covariance matrix. For whole-body fat mass, we determined that a compound symmetry structure (more parsimonious) was more appropriate. These particular model selections were guided by model diagnostic statistics (Akaike's information criteria and Schwarz's information criterion) available in SAS.
Independent variables in modeling the outcomes of interest included those variables that were biologically plausible and/or significantly related to outcome variables using Pearson's correlation analysis. These independent variables included age or TLMP, appetitive hormones (as potential mediators), liver enzyme (AST), usual physical activity (kJ/wk), energy intake (kJ/d), dietary protein (g/d), and dietary fat (g/d). Each model included site (ISU and UCD) and BMD strata (high, medium, or low) within site as obligatory explanatory variables, to account for the randomization of participants to treatment within each BMD strata at each site.
RESULTS
At baseline, 229 women in this ancillary study ranged from 45.8 to 65.0 years of age and from 0.8 to 10.0 years since menopause. The sample included mainly white women (92%), three African Americans, three Asians, one Native Hawaiian, one Native American, seven women of mixed race, two of unknown race, and two who chose not to report race. Baseline mean BMI was 24.9 T 3.0 kg/m 2 (range, 17.8-32.7 kg/m 2 ); approximately half of the women had a BMI lower than 25.0 kg/m 2 . The California site enrolled women beyond our BMI inclusion criteria (two women G18.5 kg/m 2 and seven women 929.9 kg/m 2 ).
We noted wide variability in both overall and regional body fat measures as assessed by DXA (Table 1 ) among these women. Values for circulating analytes ( Table 2) demonstrate that mean or median values were within the range reported in the literature. At baseline, assessment indicated that participants reported consuming a median (range) intake of 6,456 (1, 106 ) kJ in energy, 61 (15-168) g in protein, and 65 (17-246) g in total fat. Other dietary intakes have been reported elsewhere. 10 Physical activityYrelated energy expenditure (mean T SD [range]) was 12,768 T 8,632 (0-51,077) kJ/week. As expected, there were no between-treatment differences in any of the outcomes of interest at baseline. Moreover, we did not find significant changes in the outcomes of interest throughout the study (except for leptin and insulin) or between treatment groups at any time point.
Residual analyses for all final models (Table 3) were conducted and did not indicate violations of the assumptions of normality or homogeneity of residual variances. The 12-month treatment with soy isoflavones did not significantly affect any of the body composition measures or appetitive hormone concentrations. Time and treatment-by-time interaction did not approach significance for any model but were accounted for in each model. Site was also not a significant contributor in any model, whereas differences among BMD strata were significant for whole-body lean mass. The inclusion of covariates in the model did not alter inferences about treatment effects for any of the outcomes. However, several covariates contributed to the body composition outcomes independently of treatment. Leptin and ghrelin (inversely related to outcomes) were the common significant contributors to each of the body composition measures, with leptin exerting a stronger effect than did ghrelin. Adiponectin related inversely to all body fat measures. TLMP was associated directly with the fat mass outcomes, indicating that a longer TLMP was related, in particular, to greater androidal fat mass. The only dietary factor that emerged as significant was dietary fat intake for whole-body and androidal fat mass. In addition, we noted significant changes between baseline and 12 months for leptin (increased) and insulin (increased) concentrations, as determined by Data are presented as mean T SD. All variables were normally distributed, except for ghrelin (median, 959.6; range, 345.0-2,382.8).
a Treatment had no effect on these analytes. There were no differences among the groups in circulating analytes at any time point. paired-samples t test (Table 2 ). However, these changes were unrelated to treatment.
DISCUSSION
Several studies have reported that soy isoflavones either from dietary sources or supplements exerted significant, favorable effects on lean mass, 6 whole-body fat mass, 8 regional fat, 15, 16 or BMI. 16 In contrast, our study showed no effect of isoflavone tablets on overall or regional body composition in healthy postmenopausal women. The main strengths of our randomized, placebo-controlled clinical trial compared with previously published reports are that we included a large sample size, used two isoflavone doses (moderate, 80 mg, and high, 120 mg), continued the study for 12 months, and per-formed a state-of-the-art analysis using DXA to assess overall and regional body composition. In addition, we included appetitive hormones as potential mediators of body composition in our statistical models. However, we must point out that our study sample was rather homogeneous. Thus, our findings should be extrapolated only to a similar group of women. Our participants included healthy women, most of whom were either in the normal or overweight BMI categories and were within 5 years of menopause when they enrolled in this study. There is some evidence that the early postmenopausal period is characterized by pronounced changes in body composition, with an increase in both overall and intra-abdominal adiposity. [17] [18] [19] One possible explanation for the difference between our findings and those of previously published studies is that our Our study also examined the effect of isoflavone treatment on appetitive hormones. Although research in this area is limited, previous studies showed that a soy protein diet or isoflavone treatment significantly lowered insulin concentrations in animals 21 and postmenopausal women. 22, 23 In contrast, the consumption of a soy proteinYisoflavone (56 or 90 mg) mixture for 6 months had no significant effect on insulin concentration in postmenopausal women after taking into account the baseline insulin concentration. 24 Similarly, the consumption of a cereal bar enriched with 50 mg of isolated isoflavones for 8 weeks did not change insulin or ghrelin concentrations in 34 healthy postmenopausal women in the normal and overweight BMI categories. 25, 26 Isoflavone treatment for 93 days did not influence leptin concentration in a small sample of premenopausal and postmenopausal women. 27 In contrast, Nikander et al 28 reported that ghrelin concentration differed significantly between nondiabetic postmenopausal women with a history of breast cancer who consumed 114 mg/d of isoflavones for 3 months compared with those in the placebo control group. 28 With respect to adiponectin, there are no long-term human studies, and only one study has examined the effect of soy protein isolate on the regulation of adipokines in Wistar rats. 29 The study's findings showed that a soy protein diet increased the expression and plasma concentration of adiponectin. However, it was unclear which soy compounds influenced the outcome. In summary, there have been a few studies on the effects of soy isoflavones on appetitive hormones, with inconsistent findings. To our knowledge, our study is the first large-scale, longitudinal human trial to show that prolonged intake of soy isoflavone tablets does not affect appetitive hormone concentrations in healthy postmenopausal women.
Although isoflavone tablets did not influence the major outcomes of interest in this study, a few interesting and significant findings emerged from our analyses. Leptin was positively and ghrelin was negatively associated (consistently) with each of the outcomes of interest, whereas adiponectin was negatively associated with the fat mass outcomes. These results are in agreement with the current knowledge about the relationships between appetitive hormones and body composition. 30 Dietary fat intake was positively related to whole-body and androidal fat mass, as expected and shown in other studies. 31 In contrast, dietary fat intake or other dietary variables did not affect lean mass. In addition, the longer the TLMP, the greater the fat mass in these women, which has also been previously reported in the literature, 32 particularly for androidal fat mass. However, as expected, TLMP was not related to lean mass in these women.
CONCLUSIONS
Findings from our study do not support a claim that intake of soy isoflavone tablets for 12 months favorably affects body composition in healthy postmenopausal women. In addition, soy isoflavone tablets did not influence the appetitive hormones examined in this study. However, we noted the expected relationship between appetitive hormones and body composition (total and regional), as well as between dietary fat intake and fat mass. Body compositionVboth fat mass and lean massVis an important contributor to disease risk and health outcomes. 33 Because our results indicated that extracted soy isoflavones did not influence body composition, we cannot recommend intake of these tablets at this time to modify adiposity in healthy women.
